Revlimid is Forecast to Garner 64 Percent Share of the Total Myeloma Market in 2021, According to Findings from Decision Resources
October 2, 2012-Burlington, Mass. – Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that the multiple myeloma drug market will experience significant growth, increasing from $4.4 billion in 2011 to $7.2 billion in 2021 (a 5.2 percent annual growth) in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.
The Pharmacor advisory service entitled Multiple Myeloma finds that market growth will be driven by increasing penetration of Celgene’s Revlimid into the first-line setting and its use in combination with emerging therapies across all lines of treatment. Revlimid and Takeda/Janssen-Cilag/Janssen’s Velcade will experience increasing uptake in the relapsed/refractory setting because they will be used in combination with emerging therapies. Revlimid will be used in combination with Onyx Pharmaceuticals/Ono Pharmaceutical’s Kyprolis, Takeda/Millennium’s MLN9708 and Bristol-Myers Squibb/Abbott’s elotuzumab. Velcade will experience increased uptake in combination with AEterna Zentaris/Yakult Honsha’s perifosine and Novartis’s panobinostat.
“Although both Revlimid and Velcade will experience greater uptake in combination with emerging therapies, Revlimid will benefit most in terms of sales,” said Decision Resources Analyst Khurram Nawaz. “We forecast that Revlimid will garner impressive major-market sales of $1.6 billion in 2021 from its use in combination with Kyprolis, MLN9708 and elotuzumab. By comparison, Velcade will garner less than $70 million from its use in combination with panobinostat and perifosine.”
The findings also reveal that Velcade will remain the second highest selling agent in the multiple myeloma market despite the competition from the second-generation proteasome inhibitors Kyprolis and MLN9708 and the expected entry of less-expensive generics towards the end of the decade.
“Kyprolis and MLN9708 will benefit from physicians’ positive opinion of proteasome inhibitors for the treatment of multiple myeloma, but their sales will be overshadowed by those of first-to-market Velcade,” Mr. Nawaz said.
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.
About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.
All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.